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Abstract: Cystic fibrosis (CF) is the most common life-shortening genetic disorder in 
  Caucasians. With improved diagnosis and treatment, survival has steadily increased. 
  Unfortunately, the overwhelming majority of patients still die from respiratory failure caused 
by structural damage resulting from airway obstruction, recurrent infection, and inflammation. 
Here, we discuss the role of inflammation and the development of anti-inflammatory therapies 
to treat CF lung disease. The inflammatory host response is the least addressed component of 
CF airway disease at this time. Current challenges in both preclinical and clinical investigation 
make the identification of suitable anti-inflammatory drugs more difficult. Despite this, many 
researchers are making significant progress toward this goal and the CF research community 
has reason to believe that new therapies will emerge from these efforts.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations on chro-
mosome 7 resulting in impaired chloride transport through the cystic fibrosis trans-
membrane conductance regulator (CFTR) protein.1 In exocrine glands, this channel is 
concentrated in the apical membrane of epithelial cells and helps to regulate ion and 
water content at the luminal surface. For reasons that are not completely understood, 
CFTR deficiency causes greater activity of the epithelial sodium channel (ENaC) lead-
ing to increased absorption of sodium and water from the luminal surface. In the lung, 
this dysfunctional conductance of chloride and sodium ions reduces the water content 
and height of the airway surface liquid layer (ASL). An abnormal ASL impairs the 
mucociliary escalator causing accumulation of tenacious secretions within the airways. 
These secretions trap bacteria and other pathogens and initiate a self-perpetuating 
cycle of airway obstruction, endobronchial infection, and exuberant inflammation. 
It is not clear whether or not exuberant inflammation in the human CF airway exists 
independent of airway obstruction and infection. Regardless, evidence indicates that the 
inflammatory host response in the airway begins early in life, is of greater magnitude 
than is observed in patients without CF and persists beyond apparent eradication of 
infectious stimuli.2–8
For many years, regular use of pancreatic enzyme supplements and improved 
nutrition have greatly improved health outcomes for patients with CF. Therefore, 
pulmonary manifestations are currently the center of health impairment for most of 
these patients. For over 40 years, prescribed therapies have focused on improving Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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airway clearance of secretions and treating endobronchial 
infection. However, in recent decades, there has been a 
growing appreciation of the role of inflammation in CF lung 
disease. Excessive airway inflammation is a key component 
of the pathophysiology of CF, and researchers are working 
to identify effective and well-tolerated anti-inflammatory 
therapies.
Both prospective and retrospective studies of anti-
inflammatory medications in CF demonstrate preserved lung 
function measured by spirometry – a value closely correlated 
with survival.9–14 The majority of these studies do not show 
an increased risk of infectious complications in subjects 
receiving anti-inflammatory drugs. This paper reviews these 
studies, as well as ongoing research addressing the negative 
impacts of airway inflammation in CF.
Inflammation in CF lung disease
At birth, the lungs of neonates with CF are structurally 
normal and not inflamed. However, during early infancy, 
secretions begin to plug the bronchioles and ducts of submu-
cosal glands.2 Bronchoalveolar lavage (BAL) studies from 
infants with CF show high concentrations of neutrophils 
and proinflammatory mediators in the airways, often in the 
absence of identifiable pathogens.3,6,7 When bacteria are 
found, the inflammatory response relative to the bacterial 
burden is greater in CF infants compared with infants without 
CF.8,15 This neutrophil dominated host response is typically 
sequestered in and around the airways but spreads to involve 
the local airway wall and supporting structures in advanced 
stages. The alveoli are spared until late in the disease course, 
making CF largely an airways disease. The upper limit of 
normal for BAL from healthy lung is ,3% neutrophils. BAL 
from CF lungs typically contains 10, or even 20 times this 
degree of neutrophilia (Figure 1).
In addition to being excessive, the inflammatory response 
is also prolonged, leading many researchers to postulate that 
the exaggerated inflammatory state is largely a function of 
impaired resolution. This may explain why inflammation can 
be detected in apparently sterile BAL samples of infants with 
CF, reflecting an ongoing response to prior infection.3 As it is 
central to the host inflammatory response in the CF airway, 
anti-inflammatory therapies must address, either directly or 
indirectly, the neutrophil itself or its products.
Nuclear factor kappa-B transcriptional 
regulation
Many believe that the heightened inflammatory response 
in CF is closely related to abnormal CFTR function. This 
theory is supported by data showing increased basal and 
inducible inflammation in human airway cells with either 
genetic or chemical CFTR impairment and decreased 
inflammatory response in CF epithelial cells treated with 
CFTR correctors.16,17 Likewise, transgenic mice with 
CFTR impairment show altered inflammatory response to 
pertinent airway challenge when compared with wild-type 
mice.18,19 Much of the mechanistic research has focused on 
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Figure 1 Complex interactions contributing to CF airway inflammation. Several proinflammatory mechanisms have been identified in research of cystic fibrosis (CF) airway 
disease. Heightened proinflammatory signaling pathways, impaired redox-regulation and anti-inflammatory signaling pathways, and perpetual proteolytic and oxidative stress 
are some of the most well-described mechanisms driving the neutrophil-dominated host response. This neutrophilic inflammation, along with ineffective airway clearance and 
chronic airway infection, lead to progressive bronchiectasis and impaired lung function. 
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the   intracellular transcription factor nuclear factor kappa-B 
(NFκB). The majority of proinflammatory cytokines 
believed to be important in CF-related airway inflammation 
are regulated by NFκB activity. These include interleukin 
(IL)-8, tumor necrosis factor-alpha (TNF-α), IL-1β, IL-6, 
and granulocyte-macrophage colony-stimulating factor, 
and so on.4 Cellular interaction with bacteria, bacterial 
products, and proinflammatory cytokines causes NFκB 
to translocate to the nucleus and promote transcription 
of multiple proinflammatory gene products. It is unclear 
whether or not this transcription factor is inherently altered 
in CF. The observed increase in NFκB activation may be 
a response to the abundant stimuli present in the CF lung. 
Alternatively, there is evidence of increased Iκ-kinase 
(IKK) activity in CFTR-deficient epithelial cells. IKK is 
an important step in the canonical activation pathway for 
NFκB and over activity of this enzyme would increase 
NFκB-driven proinflammatory signaling.20–22
Studies also suggest that the local environment of 
  airway secretions surrounding CF respiratory epithelial 
cells enhances NFκB activation by increasing local calcium-
dependant signaling of this transcription factor.23 These 
data would indicate that improved airway clearance can 
indirectly reduce inflammation in the CF airway. Similarly, 
inflammatory products (eg, DNA from necrotic neutrophils, 
mucus production) add to the viscosity of airway secretions 
and further impair airway clearance. Therefore, impaired 
airway clearance and the exaggerated inflammatory state 
in the CF airway are closely linked. Effective therapies 
for either abnormality will likely improve both aspects of 
CF lung disease. Furthermore, whether or not increased 
activation of NFκB is a primary or secondary process in 
CF cells, its central role as a regulator of many downstream 
inflammatory responses makes it an obvious target for anti-
inflammatory treatment.
Anti-inflammatory signaling
Studies indicate that other immunoregulatory signaling 
pathways may be abnormal in CF. IL-10, an important anti-
inflammatory cytokine produced by many cell types in the 
lung is reduced.24,25 Lipopolysaccharide (LPS) and TNF-α, 
which are abundant in the CF airway, stimulate IL-10 
production in subjects without CF.26 However, studies of 
BAL from patients with CF unexpectedly contain relatively 
little IL-10 as compared with that from patients without 
CF.4,27 Both IL-10 and nitric oxide (NO), which is also low 
in CF, limit NFκB activation by preserving IκB. By this 
and other mechanisms, mediators such as IL-10 induce 
neutrophil apoptosis, decrease antigen presentation and 
T-cell   stimulation, and help to terminate the inflammatory 
response.28,29 Therefore, impairment of such immunoregula-
tory signaling may contribute to both the heightened and 
prolonged airway inflammatory response.
PPARγ is a transcription factor that, among other 
functions, also limits NFκB activity and is reduced in CF 
human airway epithelial cells.30,31 Abnormalities in the fatty 
acid content of CF cells, with deficiencies of both docosa-
hexaenoic acid (DHA) and linoleic acid, may contribute to 
impaired PPARγ signaling.30 Similarly, lipoxin A4 (LXA4) 
is an important endogenous anti-inflammatory lipid mediator 
that helps mitigate the acute inflammatory response.32 It has 
been reported that LXA4 concentrations are reduced in BAL 
fluid from stable CF patients compared with non-CF patients 
with pulmonary inflammation.32 Although the reasons for the 
decreased LXA4 concentrations have not been elucidated, 
administration of a metabolically stable lipoxin analog in 
cell culture and mouse models of chronic airway infection 
and inflammation decreased IL-8 production and neutro-
philic inflammation without increasing infectious burden.32 
The role of LXA4 deficiency in CF lung disease remains 
controversial and a more recent study found no difference 
in LXA4 concentration in BAL from CF patients compared 
with non-CF disease-matched controls with neutrophilic 
airway inflammation.33
T helper 17
Recent work proposes a greater role for adaptive immunity 
in CF as a subset of T cells known as T helper (TH)-17 
cells appear to be involved in CF pulmonary inflamma-
tion.34 IL-23 and IL-17 are proinflammatory cytokines 
involved in TH-17 cell signaling and are elevated in 
CF airways (human and mouse) in response to common 
stimuli.35,36 IL-17 appears to prime CF airway epithelial 
cells to greater IL-8 release in response to Pseudomonas, 
and may promote MUC5AC gene transcription through 
NFκB activation.37,38 Viscous secretions at the apical 
surface of airway epithelia trap bacteria and may magnify 
the likelihood of antigen presentation to dendritic cells 
and macrophages which, in turn, trigger the IL-23/IL-17 
signaling pathway. IL-17 is important in recruiting neu-
trophils to the airway in response to bacterial products 
such as LPS and the relative importance of IL-17 in the 
CF airway is a focus of continued research.39 These find-
ings further support the interconnected nature of impaired 
airway clearance, bacterial infection, and inflammatory 
response.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Nrf2 transcriptional regulation
Finally, recent studies in CF cell and mouse models have 
uncovered a deficiency of nuclear factor E2-related factor 2 
(Nrf2), a transcription factor functional in respiratory epi-
thelia and pivotal to mitigating the acute inflammatory 
response.40 Nrf2 regulates a large number of antioxidant 
and cytoprotective genes. Therefore, impairment of this 
transcription factor may underlie both the prooxidative and 
hyperinflammatory state. Several studies find an increased 
oxidative state in the CF airway, and reactive oxygen species, 
as intracellular messengers, are complicit in NFκB activation 
in respiratory epithelia.41 Data from CF models show low 
levels of NO resulting from a deficiency of inducible NO 
synthase in epithelial cells,42,43 and low concentrations of glu-
tathione in extracellular lining fluid, possibly due to deficient 
transport of this antioxidant through CFTR channels.44,45 
Many prooxidative and inflammatory signaling pathways are 
interrelated and, therefore, compounds with direct or indirect 
antioxidant properties may be effective anti-inflammatories. 
In support of this theory are data showing that Nrf2 ago-
nists reduce the airway inflammatory response in CF cell 
and mouse models, making Nrf2 signaling and antioxidant 
gene regulation another promising area for therapeutic 
development.46
Experiments utilizing Nrf2-knockout mice and bone 
marrow adoptive transfer show that Nrf2 function in the 
airway plays a pivotal role in both inflammatory response 
and structural damage after elastase-induced injury.47 
A significant protease/antiprotease imbalance exists in the 
CF airway, largely driven by excess free neutrophil elastase. 
This not only is a major contributor to progressive airway 
damage, but also likely helps to perpetuate the neutrophilic 
inflammatory response. Certain proteases (eg, MMP-8, 
MMP-9) abundant in the CF airway are capable of cleaving 
small peptides from collagen.48 These peptides can then 
serve as chemoattractants for neutrophil recruitment to the 
airway, demonstrating an important role of proteases in the 
inflammatory host response. Though further increased during 
pulmonary exacerbation, protease levels in the CF airway 
typically remain elevated even during times of relative health. 
Recent work highlights the ability of neutrophil elastase to 
cleave and activate MMP-9 while cleaving and inactivating 
its inhibitor TIMP-1.49 This reaffirms the neutrophil and its 
products as a central regulator and therapeutic target in the 
excessive and perpetual inflammatory state. Similarly, 2 
neutrophil serine protease inhibitors, secretory leukoprotease 
inhibitor and elafin, are both cleaved and inactivated by 
abundant neutrophil elastase in the infected CF airway.50,51 
In addition to augmenting the proteolytic imbalance, elastase 
also impairs the antimicrobial host defense properties of 
these proteins, again underscoring the need to address exces-
sive inflammation in a comprehensive treatment strategy.
Ultimately, there is evidence that many altered immu-
noregulatory pathways contribute to the inflammatory 
response in CF. Although no unified pathway directly con-
necting CFTR dysfunction to exuberant inflammation has 
been found, the combined effects of numerous dysregulated 
proinflammatory and anti-inflammatory signaling events are 
a significant part of the pathophysiology in CF lung disease. 
It may ultimately be less important to determine whether this 
is directly related to CFTR impairment or more indirectly 
due to the altered airway environment developing from 
both abnormal CFTR and ENaC channel activity. Despite 
inconsistencies in preclinical models, the majority of the CF 
research community view inflammation as a valid therapeutic 
target. This view is supported by greater lung health afforded 
from either systemic corticosteroids or high-dose ibuprofen 
in clinical trials.10,11,13 However, neither of these well-
studied anti-inflammatories is prescribed for the   majority 
of patients with CF secondary to concern over unacceptable 
side effects.52 Therefore, research continues to search for 
more suitable agents that will likely benefit the majority of 
patients with CF by addressing a fundamental component of 
ongoing airway injury.
Prior clinical trials of    
anti-inflammatory therapy in CF
Corticosteroids
Though several potential anti-inflammatory drugs have been 
studied in clinical trials of patients with CF, results from 
prior trials with 3 medications largely drive this field of 
research: systemic corticosteroids, high-dose nonsteroidal 
  anti-inflammatory drugs (NSAIDs), and azithromycin. 
Nearly 3 decades ago, investigators noted that patients 
with CF who also had hypogammaglobulinemia treated 
with systemic corticosteroids had better lung function than 
those without hypogammaglobulinemia (and therefore 
not treated with steroids).53 This led to 2 large clinical 
trials of oral steroids in patients with CF. An initial study 
enrolled 21 patients aged 1–12 years with mild to moder-
ate lung disease, given with either placebo or prednisone 
1–2 mg/kg by mouth every other day.9 Subjects receiving 
prednisone showed better lung function, improved weight 
gain, and few hospitalizations over a 4-year observational 
period. No apparent adverse events were reported during 
this study, which led to a larger, multicenter trial, enrolling Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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285 patients aged 6–14 years with mild to moderate lung 
disease.54 Prednisone 1 mg/kg or 2 mg/kg by mouth every 
other day was compared with a placebo group, and again 
showed beneficial effects of corticosteroids on lung function 
– particularly in subjects infected with Pseudomonas 
aeruginosa. However, significant adverse events occurred 
in those receiving prednisone, including growth impair-
ment, cataracts, and glucose intolerance. The high-dose 
(2 mg/kg) group was halted half way through the 4-year 
study due to a high incidence of adverse events.55 Follow-up 
analysis 6 years after completion of the trial found persis-
tent growth deficits,56 and a separate analysis 5 years after 
the initial smaller study found growth deficits in 14/17 
subjects in the prednisone arm who completed the study.12 
For these reasons, regular use of systemic corticosteroids 
is not recommended for patients with CF, despite the ben-
eficial effects on pulmonary health. It is, however, worth 
noting that those receiving prednisone in these trials did 
not show greater risk of infection. Though unacceptable 
as a long-term therapy for most patients, shorter courses 
of systemic steroids may be useful,57 particularly for those 
with a prominent asthmatic phenotype or during treatment 
for acute pulmonary exacerbation when the inflammatory 
response is further increased.
The use of inhaled corticosteroids (ICS) to treat CF lung 
disease has been a topic of much interest in recent years. 
This therapy continues to be prescribed to a large number of 
patients, likely due to a relatively high incidence of asthma-
like symptoms in patients with CF and the perceived safety 
and familiarity among health care providers. However, in 
clinical trials subjects with CF, ICS have not consistently 
proven effective. A recent Cochrane Database Systematic 
Review of clinical trials found no conclusive benefits of ICS 
in CF and no apparent adverse events when discontinuing 
ICS.58 Authors also noted that data are not available to deter-
mine if long-term use of ICS will reduce lung inflammation 
in CF, and that this question is unlikely to be answered by a 
clinical trial at this point.
Ibuprofen
Seeking to identify an anti-inflammatory drug that might be 
better tolerated, Konstan et al59 in Cleveland began studying 
the use of high-dose ibuprofen in animal models, and then 
in clinical trials of patients with CF. A 4-year double-blind 
placebo-controlled trial in 85 subjects aged 5–39 years with 
mild lung disease showed that those receiving the NSAID had 
less decline in pulmonary function, preserved body weight, 
and fewer hospitalizations.11 Individual pharmacokinetics 
targeting a peak plasma concentration of 50–100 µg/mL 
(typical dose 20–30 mg/kg) were used in this study. This 
is 2–3 times higher than commonly prescribed doses and 
in vitro studies indicate that, at this concentration, ibuprofen 
may inhibit pertinent proinflammatory signaling events in 
the cell (ie, NFκB, AP-1 activation).60,61 A second trial was 
conducted in Canada with 142 subjects over 2 years and 
showed preserved forced vital capacity and a trend toward 
preserved forced expiratory volume in 1 second (FEV1) in 
the ibuprofen arm compared with placebo.13 The incidence 
of adverse events between placebo and ibuprofen did not 
significantly differ in these trials, and in the Canadian study 
a greater number of subjects receiving placebo dropped out 
of the study due to adverse events that could be attributable 
to NSAID therapy. This observation likely underscores the 
reason that fewer than 10% of patients with CF in the United 
States currently receive high-dose ibuprofen. The underlying 
disease often manifests with symptoms that overlap with 
NSAID toxicity (eg, abdominal pain, epistaxis, hemoptysis, 
gastrointestinal hemorrhage) and confusion or concern of 
these apparently rare, though at times dramatic, events is 
the reason most cited by practitioners for not prescribing 
this therapy.52 The need for individual pharmacokinetics has 
also been cited as a limitation to ibuprofen use.
Azithromycin
Azithromycin is a commonly prescribed therapy for CF and 
likely has immunomodulatory effects. Data indicating that 
regular use of macrolides afforded better pulmonary health 
in another chronic lung disease, diffuse panbronchiolitis, 
led to studies in CF, including a trial of azithromycin in 185 
patients with CF who had mild to moderate lung disease and 
were infected with P . aeruginosa.62 This multicenter, placebo-
controlled trial found that subjects given azithromycin thrice 
weekly had better lung function, weight gain, quality of life, 
and fewer pulmonary exacerbations than those given placebo. 
Studies conducted in the United States and abroad similarly 
showed that chronic azithromycin provides clinically relevant 
health benefits, though more consistently so in those infected 
with P . aeruginosa.63,64 Many mechanistic studies have 
since been done to better understand how azithromycin is 
  beneficial. From data available to date, it appears that there 
is a combined effect of both anti-inflammatory and anti-
infective properties. Azithromycin can inhibit neutrophil 
recruitment and oxidative burst, as well as proinflammatory 
cytokine production.65–67 This macrolide antibiotic also inhib-
its several virulence factors of P . aeruginosa, which may be 
more susceptible to azithromycin in the stationary growth Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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phase.68 The question of mechanism is further complicated by 
recent studies in both CF mouse and human models showing 
that treatment with azithromycin causes increased rather 
than decreased release of pivotal proinflammatory cytokines 
from primary airway epithelial cells.69,70 Similarly, sputum 
concentrations of IL-8 were not significantly altered in the 
largest US clinical trial of azithromycin in CF patients and 
patients receiving this treatment continue to have significant 
airway neutrophilia.62
Though not always reflected in spirometry, the clinical 
benefits of azithromycin therapy in CF appear to be sig-
nificant. However, the complexities noted above combined 
with an increased incidence of nausea and vomiting and 
increased antibiotic resistance71 (eg, Staphylococcus aureus, 
nontuberculous mycobacteria) with chronic use, lead many 
to conclude that this therapy is useful but not the ideal anti-
inflammatory treatment for CF. Recent data from a large clini-
cal trial suggest that azithromycin use for 24 weeks may not 
significantly affect pulmonary function in children without 
chronic P . aeruginosa infection.72 Despite the fact that FEV1, 
the primary outcome measure, was not affected, other poten-
tially important exploratory outcomes were improved with 
azithromycin use (eg, rate of pulmonary exacerbation).
There are many challenges to identifying a more suitable 
anti-inflammatory therapy. Despite what has been learned 
from prior research, the proper molecular targets are not clear 
and there is significant redundancy in proinflammatory signal-
ing within the lung. Highly specific drugs targeting individual 
pathways have often proven ineffective or potentially toxic. 
Those with the greatest proven clinical efficacy appear to have 
broad, rather nonspecific effects, which may predispose to 
more side effects. Despite these challenges, ongoing research 
is identifying multiple new and promising therapeutic targets, 
and there is significant hope that more effective and well-
tolerated therapies will be identified in the near future.
Challenges in preclinical models 
when testing new therapies
An essential step in developing new anti-inflammatory 
therapies is use of preclinical models to identify molecular 
targets and test drug activity. Although these models have 
provided fundamental information for our understanding 
of the role of inflammation in CF lung disease, each model 
under current use has limitations for the evaluation of  can-
didate therapies. Available cell culture and animal models 
are unable to reproduce the chronic airway impaction and 
infection underlying the perpetual inflammatory response. 
As highlighted earlier, the interrelated nature of multiple 
processes in the CF airway (chronic infection, airway obstruc-
tion, and host inflammatory response) is clear. Therefore, 
improved methods, likely employing better animal models, 
will be necessary to more accurately predict clinical utility 
when testing promising candidate therapies.
Cell lines and cultured epithelial cells
A comprehensive list of established cell lines used in CF 
research is beyond the scope of this article, but has been 
reviewed.73 Use of immortalized cell lines from patients 
with CF has been especially useful to study the effects 
of CFTR dysfunction and to test drugs that may improve 
CFTR function.73,74 Some features of the CF inflammatory 
response have been demonstrated in primary and immortal-
ized CF cells, such as an increased inflammatory response 
following P . aeruginosa exposure,75,76 and higher levels of 
proinflammatory cytokines and nuclear transcription factors 
involved in the inflammatory pathway.25,77–80 However, it is 
unlikely that the immunologic response to chronic bacterial 
infection seen in the CF lung can be fully reproduced in 
either cultured primary cells or in immortalized cell lines. 
For example, phenotypic characteristics that are expressed 
by a particular clone from an immortalized cell line may not 
completely reflect that of the original mixed population of 
epithelial cells from which it was derived. Furthermore, the 
transformation process and cell passaging (or in the case of 
primary cells, transferring the cells into culture) can lead to 
differential expression of phenotype. Finally, cells in vitro 
have a limited ability to tolerate live bacterial challenge, and 
the strain of P . aeruginosa that is used in an experiment can 
influence the inflammatory response.73 In vitro cell culture 
studies have been extremely useful in CF inflammation 
research and models are being improved to better recapitulate 
the human airway. However, it appears unlikely that these 
methods, in isolation, will be adequate to accurately predict 
the most promising drugs for clinical trials.
Animal models
The mouse, which has 78% sequence homology with humans, 
has been used extensively in CF research.81 Mice are relatively 
inexpensive, easy to produce and to manipulate genetically, 
and widely available compared with other CF animal models. 
However, there are differences in airway morphology between 
the mouse and human.82,83 More importantly, although many 
CF mouse models show exaggerated inflammatory response 
in the airway and certain mice demonstrate aspects of altered 
pulmonary physiology consistent with CF lung disease, 
none develops the full spectrum of chronically inflamed Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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and infected airways.84 Furthermore, the phenotype of each 
mutant mouse is dictated not only by the Cftr mutation, 
but also by the genetic background and environment of the 
animal, making proper controls essential in these studies.84 
For many reasons, the CF mouse has been a useful in vivo 
mammalian model for inflammation research; however, 
present limitations must be considered when using these 
animals to determine clinical promise of new therapies.
Because of the limitations posed by the mouse model, 
researchers have investigated use of other animal models 
with the hope that lung function, size, and architecture 
would be more like that of humans. The sheep, ferret, 
and the pig, each having .90% sequence homology with 
humans, are models under development.85–88 Early data from 
the CFTR -/- pig shows that the newborn piglets have nasal 
voltage measurements consistent with CFTR dysfunction 
and pancreatic exocrine insufficiency.89 Recent reports from 
5 CF pigs surviving to several months of age indicates that 
they may develop a lung phenotype similar to that seen in 
humans.90 If survival for these animals can be improved and 
this model does consistently develop lung disease similar 
to that of humans, the model will be humans, it will be an 
invaluable resource for testing new drug therapies. Practical 
considerations of cost and broad availability to the research 
community will also need to be addressed in this process. 
Finally, it should be noted that thus far, survival of CF piglets 
has required intestinal surgery at birth performed by skilled 
investigators.
Challenges for design of clinical 
trials when testing new therapies
Until an adequate animal model of CF lung disease is 
developed, much of the efficacy and safety data must be 
generated in human subjects with CF for new therapies that 
show promise in current preclinical models. As an orphan 
disease with only approximately 30,000 patients in the United 
States and 70,000 worldwide, the number of patients available 
to participate in clinical trials is limited.91–93 Furthermore, 
because it is a progressive, multisystem disease, there is 
wide variability in disease burden between patients. Potential 
confounders that must be considered in trial design and 
analysis include but are not limited to pulmonary function, 
gender, bacterial infection, presence of CF-related diabetes, 
mutation class, pancreatic function, and nutritional status.74
Large, placebo-controlled, double-blinded, multicenter 
clinical trials are necessary to provide adequate data for 
Federal Drug Administration (FDA) approval. However, to 
demonstrate that these large trials are warranted, smaller 
trials that evaluate efficacy and safety of a candidate drug 
must be conducted first. One such trial design is the proof 
of concept.81 A successful proof of concept study provides 
positive outcome data that is specific to the biological 
process the drug is intended to effect. It should also provide 
preliminary data that reflects that the drug is safe. In addi-
tion, because pharmacokinetics often differ in patients with 
CF,94–96 it is important to establish appropriate dosing prior 
to progressing to large trials of a new drug. In consideration 
of all these factors, design of proof of concept trials must 
include stringent inclusion and exclusion criteria, collection 
of outcome measures that support the biologic effects of the 
drug, and pharmacokinetic data that suggests the chosen 
dose is adequate for patients with CF. These requirements 
must be balanced so that the cost and burden to subjects will 
not prevent completion of the study. Study design of these 
initial trials is critical as CF studies, similar to those of many 
orphan diseases, can easily become underpowered to detect 
significant differences in the primary outcomes. This makes 
it difficult to justify larger, more costly studies and promising 
new therapies may be lost to future development.
One of the most significant challenges to testing 
new therapies in CF is determining appropriate outcome 
  measures. Outcomes used in clinical trials for treatment 
with anti-inflammatory therapies have traditionally included 
clinical efficacy measures such as time to next exacerbation, 
or surrogate end points such as pulmonary function (usually 
FEV1 and/or rate of decline of FEV1).10,11,13,14,97,98 As a result 
of improvements in clinical care, the rate of decline of lung 
function in patients with CF has slowed substantially.99 In 
addition, rates of exacerbation in patients with relatively 
less lung damage are lower than in those with more 
severe disease.100 However, it is these patients who may 
benefit most from anti-inflammatory treatment to prevent 
pulmonary decline over time. Thus, using lung function or 
pulmonary exacerbations as primary end points in clinical 
trials requires a large number of patients over a significant 
length of time to detect differences in these clinical 
parameters.101 The FDA is increasingly accepting and 
encouraging the use of measures designed to assess Patient 
Reported Outcomes (PROs) such as health-related quality 
of life (eg, the Cystic Fibrosis Questionnaire-Revised).102 
However, this may be problematic when studying a chronic 
therapy aimed at reducing the rate of decline in health 
over a lifetime. As in the case of FEV1 and pulmonary 
exacerbations, either prohibitively long follow up or large 
numbers of subjects may be needed to detect a significant 
difference in PROs.74Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Given the limited numbers of potential research subjects 
and the need to maximize limited resources, early phase 
  studies must delicately balance the risk of underpowered 
results with the burden of subject participation and cost. For 
new anti-inflammatory therapies, other outcome measures 
may be more sensitive for detecting short-term response to 
treatment. In recognition of the need to develop and   implement 
novel outcome measures for use in CF clinical research, the 
Cystic Fibrosis Foundation (CFF) Therapeutics Development 
Network (TDN) established outcome-measures working 
groups to make recommendations.103 Mayer-Hamblett et al103 
also defined standards by which new outcome   measures 
should be evaluated: a new   outcome measure should be bio-
logically relevant, sensitive and   specific to treatment effects, 
reproducible, and feasible. The remainder of this portion of 
the review focuses on potential outcome measures for use in 
trials of new anti-inflammatory therapies.
Systemic biomarkers
Because a systemic biomarker of inflammation would be 
readily obtainable (in blood or urine) from a patient of any 
age and with any severity of pulmonary disease, researchers 
have evaluated such measures in patients with stable disease 
and in those experiencing exacerbations.104–119 Although, 
some systemic markers have shown response to systemic 
antibiotic therapy,104,110,112,115,120 there is concern that approach 
may not be sufficiently sensitive to detect changes that are 
occurring in the lung in response to a new anti-inflammatory 
therapy (Table 1).121
Bronchoalveolar lavage
The lung or, more precisely, the airway is the most active site 
of CF-related inflammation; thus, there has been substantial 
focus on developing biomarkers that are measurable in airway 
samples. Bronchoscopy with BAL is considered the gold 
standard for evaluation of lung inflammation, and has been 
used to evaluate response to therapy in many CF clinical 
trials.122–131 However, this procedure is invasive, resource 
intensive and samples only a small portion of the lung.121 
Two less invasive means of capturing airway specimens are 
exhaled breath condensate (EBC) and sputum collection.
exhaled breath condensate
EBC collection allows measurement of markers even in those 
CF patients who do not produce sputum. Markers of inflam-
mation, NO, and pH have been studied in the EBC of adult 
and pediatric patients with CF.132–139 In some studies, pH and 
markers of inflammation in EBC from patients with CF who 
are experiencing an exacerbation have been shown to respond 
to antibiotic therapy.132,136,138 In response to the increasing inter-
est in use of EBC to study pulmonary disease, the American 
Thoracic and European Respiratory Societies collaborated to 
make recommendations for optimal collection and analysis 
techniques.6 These efforts are promising, though concerns 
over sensitivity and specificity of this technique have been 
expressed. Many traditional inflammatory indices may not be 
volatile enough to accurately measure by this technique.
Sputum biomarkers
More extensive work has been done by CF researchers to 
evaluate the use of sputum biomarkers to sample lower airway 
secretions and response to therapy. Because patients with 
mild disease rarely produce sputum when stable, some studies 
have utilized sputum induction. For example, Ordonez et al140 
studied pretherapy and posttherapy inflammatory markers 
in induced sputum following treatment with IV antibiotics. 
Table 1 Current and potential outcome measures for use in clinical trials of new anti-inflammatory therapies in CF
Outcome measure Examples Reference(s)
Clinical efficacy Fev1, rate of decline of Fev1, rate of exacerbations 10, 11, 13, 14, 97, 98
Patient reported  
outcome
CF-HQR 102
BAL markers Neutrophils, bacterial count, elastase IL-8, TNF-α,  
soluable ICAM-1, LB4
122–131
eBC markers NO, pH, MMP-9 132–139
Sputum markers white cell count, bacterial count, elastase IL-6, 
IL-8, IL-10, TNF-α
140–143
Systemic markers CRP, Ne-APC, TNF-α, IL-1, IL-2, IL-8, eGF 104–119
CT scan CT score, airway trapping, airway wall thickening 145–152
MRI Structural changes, lung perfusion/pulmonary blood  
flow, ventilation defects
154–158
Note: Table does not include exhaustive list of examples for each outcome measure. For comprehensive review of outcome measures in clinical trials for CF patients/
candidate biomarkers for CF airway inflammation. See references 74 and 121.
Abbreviations: Fev1, forced expiratory volume in 1 second; IL, interleukin; TNF, tumor necrosis factor; L, leukotriene; NO, nitric oxide; MMP, matrix metalloprotein; CRP, 
C-reactive protein; Ne-APC, neutrophil antiproteinase complex; eGF, endothelial growth factor; CT, computed tomography; MRI, magnetic resonance imaging; CF, cystic fibrosis.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Total sputum white cell count, active elastase, IL-8, and 
P . aeruginosa counts were significantly decreased after anti-
biotic therapy.140 Although sputum induction was used in this 
study, expectorated sputum has also been shown to reflect 
airway inflammation in CF.141,142 Sagel et al143 demonstrated 
that in patients with CF, measurement of inflammatory mark-
ers is comparable in induced and expectorated sputum. Thus, 
either method can be successfully employed in clinical trials 
in which sputum biomarkers will be an end point.
To assess the association between sputum biomarkers 
and clinical parameters, Mayer-Hamblett et al101 constructed 
a database of sputum biomarkers and pulmonary function 
data from 4 multicenter CF clinical trials to demonstrate 
the strength of association between expectorated sputum 
biomarkers and lung disease severity. Both elastase and 
IL-8 were negatively correlated with lung function in this 
diverse group of CF patients. Of the markers tested, sputum 
elastase showed the strongest correlation with FEV1 (correla-
tion, 0.35; 95% confidence interval [CI], −046 to −0.22). On 
average, CF patients whose sputum elastase measurements 
differed by 0.5 logs differed in their FEV1 values by −7.3% 
(95% CI, −9.7 to −4.6). Finally, sputum elastase was shown 
to have a significant longitudinal association with FEV1: 
a −2.9% decline in FEV1 for every log increase in elastase. 
Thus, differences in sputum elastase correlated well with 
clinically meaningful differences in lung function, providing 
a useful biomarker, particularly for studies in which the inter-
vention would likely preserve function through mechanisms 
that would also reduce the airway elastase concentration.101
Aware that differences in collection of sputum and analysis 
of biomarkers may lead to variability in results, and thus 
decrease the reproducibility of test results, the CFF TDN created 
standard operating procedures (SOPs) for both collection of 
sputum by induction and processing of sputum.121 In addition, 
core laboratories were established for analysis of sputum 
inflammatory biomarkers and sputum cytology (The Children’s 
Hospital/University of Colorado Health Sciences Center and 
Case Western Reserve University, respectively.) Use of SOPs 
and core laboratories for centralized analysis will insure 
consistency of results from single and multicenter studies.
Computed tomography (CT)
Although induced sputum and EBC can be collected from 
children (as young as 10 years for induced sputum121 and 
3–4 years for EBC,)144 neither procedure is feasible in very 
young children and infants. Imaging such as CT and magnetic 
resonance imaging (MRI) would be applicable to subjects 
of all ages. Furthermore, therapies aimed at correcting the 
basic defects in CF are hoped to prevent or delay the onset 
of functional lung disease. Airway imaging would allow 
researchers to serially assess the presence and progression 
of structural lung damage.
Two separate longitudinal studies in patients with CF 
using every 2 or 3 year CT scans showed that scored CT 
images were more sensitive than spirometry for detecting 
disease progression.145,146 In addition, Brody et al147 showed 
that there was correlation between the frequency of pulmo-
nary exacerbations and CT score. Small intervention studies 
in patients with CF have demonstrated improvement in overall 
CT score following treatment.148,149 
In addition to evaluation of general structural changes, 
CT scan can be used to reproducibly measure airway wall 
thickness. Airway wall thickness can be reproducibly 
measured by CT scan.150–152 Because airway wall thickness 
is thought to correspond to airway inflammation, this 
measurement may be useful to monitor the efficacy of anti-
inflammatory therapies. Airway wall thickness has been suc-
cessfully used to demonstrate response to inhaled steroids in 
asthmatic subjects.153 More data are needed to determine if this 
outcome measure will be useful in anti-inflammatory studies 
in CF lung disease. Investigators are faced with concerns over 
cumulative radiation exposure and potential need for sedation 
in the very young when designing these experiments.
Magnetic resonance imaging
Using proton-MRI sequences, structural changes such as 
bronchial wall thickening, mucus plugging, bronchiectasis, 
consolidation, and segmental destruction can be visualized.154 
Although the spatial and temporal resolution of MRI of the 
lung is inferior to that of CT, the lack of ionizing radiation 
makes MRI appealing as a repeated measure in clinical trials. 
Use of intravenous or inhaled contrast expands the potential 
of MRI in assessing CF lung disease. For example, with 
gadolinium-based intravenous contrast, MRI can examine 
lung perfusion and pulmonary blood flow.155,156 Inhaled 
hyperpolarized gas can provide a high MRI signal from 
airspaces of the lung. No ionizing radiation is used for these 
contrast studies and reported adverse events are mild.157 Using 
ventilation MRI imaging, Mentore et al158 demonstrated 
correlation between ventilation defects and spirometry. Fur-
thermore, MRI imaging correlated with treatment and could 
detect abnormalities in subjects with normal spirometry. As 
in the case of sputum biomarkers, in order to use imaging 
techniques as outcome measures in clinical trials, SOPs will 
need to be created, and centralized reading centers where a 
common scoring system is used must be developed.159Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Future directions
CFF pipeline-drug discovery program/CF 
therapeutics development network
Through research funded by the CFF, both ibuprofen and 
azithromycin were shown to be beneficial in CF as described 
earlier. The CFF TDN is sponsoring a number of trials of 
potential new anti-inflammatory drugs, including both novel 
compounds and drugs that are FDA approved for other 
indications.160 Based on promising preclinical data, 3 FDA-
approved drugs were recently tested in proof of concept trials 
including the immunosuppressant hydroxychoroquine, the 
HMG CoA reductase inhibitor, simvastatin and the PPAR 
gamma agonist, Pioglitazone.161–163 Although results of safety 
and efficacy of these 3 therapies were inconclusive, consid-
eration is being given for longer trials.164
Another FDA-approved therapy, the phosphodiesterase 
inhibitor, sildenafil, is being studied through the CF TDN 
for its potential as an anti-inflammatory. Toward et al165 
demonstrated that pretreatment with sildenafil inhibited 
LPS-induced airway hyperreactivity, white cell influx, and 
NO dysfunction in 2 guinea pig models of airway disease.165 
In CF respiratory epithelial cells, Poschet et al166 showed 
that sildenafil exposure could reverse the excessive proin-
flammatory response to P . aeruginosa. In separate work, 
DBA/2 mice sensitive to P . aeruginosa were fed a diet 
with or without sildenafil. Following aerosol-delivered P. 
aeruginosa respiratory infection, myeloperoxidase in lung 
homogenates (a reflection of neutrophil infiltration) was 
reduced by 42% ± 11% (P = 0.047) in animals who received 
sildenafil-containing diets.167 Based on these data, sildenafil 
is currently being tested in a phase 2 trial.
A novel drug that is under investigation through the CF 
TDN is SB656933, a selective chemokine receptor (CXCR2) 
antagonist. This once-daily oral medication is also in a phase 2 
multicenter study. The CFF is also funding investigation of 
drugs that may combat the pathogenic result of excessive 
inflammation by targeting antioxidant deficiencies. The ability 
of N-acetylcysteine (an oral agent that replenishes glutathione 
levels) to modulate inflammation in CF was studied by Tirou-
vanziam et al.168 In this proof of concept study, CF patients were 
treated for 4 weeks, and inflammatory markers in expectorated 
sputum were assessed. In addition to increased glutathione lev-
els in blood and in neutrophils, researchers found that sputum 
elastase was significantly decreased following treatment with 
N-acetylcysteine. Based on these results, a multicenter phase 
2b is underway.   Targeting similar mechanisms, a phase 2 trial 
of inhaled glutathione is being conducted in Germany. Finally, 
a multicenter study of DHA supplementation is also ongoing. 
As discussed earlier, DHA supports anti-inflammatory 
signaling that may be impaired in CF (eg, PPARγ).
In summary, preclinical models of CF have provided 
invaluable information about the pathophysiology of CF lung 
disease, highlighting many molecular mechanisms which 
promote an exaggerated host inflammatory response. However, 
significant limitations of these models present challenges when 
trying to identify promising anti-inflammatory therapies for 
clinical trials. Similarly, inherent qualities of CF (eg, variable 
disease burden, relatively slow progression, limited number 
of potential subjects, etc) require thoughtful planning for early 
human studies to balance patient burden and cost with risk of 
underpowered data. Improving preclinical models of CF lung 
disease and developing useful and more dynamic surrogates 
of pulmonary function (ie, biomarkers) will help to overcome 
these challenges and significantly accelerate progress toward 
identifying new anti-inflammatory therapies. The CF research 
community continues to identify and test promising drugs, 
while many patients benefit from those already in use.
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